Monoclonal antibodies resources and updates

Monoclonal antibody treatment was given emergency use authorization by the U.S. Food and Drug Administration as a COVID-19 treatment in November 2020. The therapy, which is used in people who are at a higher risk of being hospitalized with COVID-19, boosts a person’s natural immune system so it’s stronger and better able to fight the coronavirus. It can be given to both vaccinated and unvaccinated people and stays in the body for around 90 days.

• Monoclonal antibodies update from Dr. Jeffrey Fischgrund, July 28
• Monoclonal antibodies update from Dr. Paul Chittick, April 5
• Monoclonal antibodies update from Dr. Paul Chittick, Jan. 26
• Monoclonal antibodies update from Dr. Jeffrey Fischgrund, Jan. 11
• Monoclonal antibody order form (Bebtelovimab)
• What is monoclonal antibody treatment and when is it needed?
  

Evusheld resources and updates

Evusheld (tixagevimab/cilgavimab) is a long-acting monoclonal antibody that was recently issued an emergency use authorization (EUA) by the Food and Drug Administration (FDA) for COVID-19 pre-exposure prophylaxis (PrEP) in certain high-risk, immunocompromised individuals. It is administered through two intramuscular injections, repeated every six months. PrEP is not a substitute for vaccination.

• Evusheld ordering form
• Prioritization and Scarce Resource Allocation of Evusheld for COVID-19 Pre-Exposure Prophylaxis in Certain High Risk Individuals, Michigan.gov
• FAQ for health care providers
• FAQ for patients and caregivers

If you have questions regarding Evusheld, please contact Dr. Paul Chittick, section head, Infectious Diseases, Beaumont, Royal Oak.